Table 4.
Comparison of demographic and clinical characteristics according to therapy
| Monotherapy (n=33) No. (%) | Combination therapy (n=213) No. (%) | p-value | ||
|---|---|---|---|---|
| Division | Surgical oncologist Medical oncologist | 27 (13.1) 6 (15.0) | 179 (86.9) 34 (85.0) | 0.7478† |
| Age | Median (range) | 71 (30 - 84) | 62 (27 - 80) | 0.0469‡ |
| ECOG | 0, 1 2 | 29 (12.1) 4 (66.7) | 211 (87.9) 2 (33.3) | 0.0034^ |
| Gender | Male Female | 18 (12.7) 15 (14.4) | 124 (87.3) 89 (85.6) | 0.6912† |
| Stage | II III IV | 20 (27.8) 12 (7.1) 1 (20.0) | 52 (72.2) 157 (92.9) 4 (80.0) | < 0.001^ |
| Differentiation | Well Moderate Poor Unknown |
2 (8.3) 27 (13.7) 2 (14.3) 2 (18.2) |
22 (91.7) 170 (86.3) 12 (85.7) 9 (81.8) |
0.8225^ |
| Operation | Laparotomy Laparoscope |
14 (13.2) 19 (13.6) |
92 (86.8) 121 (86.4) |
0.9339† |
| Preoperative CEA (ng/mL)# | Median (range) | 4.2 (0.94 - 50.2) | 3.4 (0.2 - 260.8) | 0.3455‡ |
Monotherapy: Capecitabine, 5-FU/LV (5-fluorouracil and leucovorin), and UFT/LV (uracil-tegafur and leucovorin)
Combination therapy: FOLFOX (leucovorin, 5-fluorouracil, and oxaliplatin), CAPOX (capecitabine and oxaliplatin)
#Missing value: 2 in monotherapy, 8 in combination therapy
†Chi-square test; ^Fisher's exact test, ‡ Mann-Whitney U test